Skip to content
Search our Site
Search our site
Search our site
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Surgery research papers
Long-term outcome of subthalamic nucleus DBS in Parkinson's: From the advanced phase towards the late stage of the disease?
This study confirms the long-term safety and efficacy of STN-DBS in PD. Nevertheless, the functionality of patients worsens over time, mainly for the onset and progression of levodopa-resistant and non-motor symptoms. The role of PD-subtype seems to be relevant in the long-term outcome.
10 February 2014
Progression and survival in Parkinson's disease with subthalamic nucleus stimulation
Results: The mean annual change based on baseline and last observation scores in individually matched groups was 0.97 (SD = 3.57) for the surgery group and 1.04 (SD = 3.33) for the controls and thus not significantly different, F(1, 104) = .21, P = 0.89. The long-term mortality was also similar in the two groups during long-term follow-up, hazard ratio = 1.76, CL 0.913.40, P = 0.091.
04 February 2014
Phonemic verbal fluency decline after STN DBS does not depend on number of microelectrode recordings or lead tip placement
Conclusions: Significant decline in phonemic verbal fluency did not correlate with surgical passes nor with location of the lead tip or active stimulation site. These data suggest that age may influence verbal fluency decline more than surgical technique.
03 February 2014
Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials
Although the number of RCTs obtained is small, the total sample size is relatively large, confirming the efficacy of DBS in the control of motor signs and improvement of patients' functionality and quality of life. More controlled research is required on the neurocognitive and psychiatric effects of DBS.
02 February 2014
Urinary profile of catecholamines and metabolites in Parkinson patients with deep brain stimulation
Conclusion: After DBS-STN, the DA/l-DOPA ratio, an indirect measure of DA synthesis, increased. These results show that DBS-STN may improve the efficacy of oral levodopa.
01 February 2014
STN-DBS does not change emotion recognition in advanced Parkinson's disease
In a sample of 30 patients 6 had depression or apathy at baseline that significantly increased to 14 post-surgery. There were no significant changes in the tests of identity discrimination, discrimination of emotional faces, naming of emotional faces, recognition of emotional prosody, and naming of emotional prosody after STN-DBS. The results of emotion tests could not predict the development of the neuropsychiatric symptoms.
01 February 2014
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs.
23 January 2014
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease
Interpretation: ProSavin was safe and well tolerated in patients with advanced Parkinson's disease. Improvement in motor behaviour was observed in all patients.
10 January 2014
Effect of subthalamic nucleus deep brain stimulation on driving in Parkinson disease
DBS of the STN seems to have a beneficial effect on driving ability in patients with PD, potentially because of nonmotor driving-relevant aspects. Our data suggest that driving permission for DBS-treated patients with PD should not be handled more restrictively than permissions for patients with PD in general.
07 January 2014
The impact of age and disease duration on the long term outcome of neurostimulation of the subthalamic nucleus
Conclusion: STN-DBS is an efficient treatment of advanced PD for all treated age-groups. Provided strict inclusion criteria are respected, older age and longer disease duration are associated with slightly worse effects mainly on L-dopa-resistant symptoms.
01 January 2014
Back to Top
Add page to PDF basket
Copyright © 2014 EPDA. All Rights Reserved.
Privacy and cookies